Mathias Oelke

CSO - Head of Preclinical Immunotherapy and Platform Development

About

Accomplished Ph.D. scientist and business partner with 20 years experience in cancer immunotherapy and deep expertise in immunology with specific focus in T-cell biology, has developed a robust immune focused platform technology and has co-founded a start up biotech company. • Robust background in Immunology and molecular biology; currently SVP, Head of Pre-Clinical and Platform Development at NexImmune and adjunct Professorship at JHU in Baltimore. • Developed and advanced the AIM platform technology, which is a cassetable system based on artificial antigen presenting cells (aAPC’s) with broad utility in immunotherapy. The system can be used to develop therapeutics, adoptive cellular therapies, robust target discovery and validation, and the potential to enable efficient cellular manufacturing capabilities. • Co-founded NexImmune along with Jon Schneck and Ken Carter, a start up biotech that spun out of JHU and is currently based in Gaithersburg • Additional contributions: Robust and successful tech transfer, established NexImmune lab and ensuring appropriate talent identification and management for NexImmune, and advanced technology to GMP development. In summary Dr. Oelke is an expert in cellular immunology, T cell research and a pioneer of the "artificial Antigen Presenting Cell" technology. He has a solid network of collaborations within the USA as well as all over Europe, he is co-owner of over 15 patents around the aAPC technology and additional pending patent applications in related fields cancer immunotherapy.

Country

United States

City

Parkville

Industry

Biotechnology

Skill

Tactical Planning, Publications, Assay Development, Research and Development (R&D), Publication Planning, Executive Leadership, artificial Antigen Presenting Cells, aAPC, Immunotherapy, T cells, Molecular Biology, Cell Biology, Cell Culture, Biotechnology, nano particles, Nano-aAPC, Cell, Cancer, Biochemistry, Chemistry, Flow Cytometry, Immunology

Experience

CSO - Head of Preclinical Immunotherapy and Platform Development

NexImmune, Inc.

2022-4 - Present · 4 yrs 6 mos

SVP - CSO - Head of Preclinical Immunotherapy and Platform Development

NexImmune, Inc.

2019-5 - 2022-11 · 3 yrs 7 mos

VP - CSO - Head of Preclinical Immunotherapy and Platform Development

NexImmune, Inc.

2017-1 - 2022-11 · 5 yrs 11 mos

Senior Director, Discovery

NexImmune, Inc.

2014-11 - 2017-6 · 2 yrs 8 mos

Gaithersburg

My responsibilities include building the chemical, cellular and molecular biology lab. In less than 6 month we had a fully operational lab reproducing data previously generated at JHU. Since the lab is established I oversee the R&D program at NexImmune and am focused on modifying and optimizing the aAPC platform from the research bench into a clinical product ready for GMP production. In addition, I am involved in product and process development, negotiated with CRO’s and CMO’s, timeline planning, budget design and data analysis and presentation both internally and externally including investor presentations.